Synjardy

Synjardy (empagliflozin and metformin hydrochloride) is a combination of a sodium-glucose co-transporter 2 (SGLT2) inhibitor and a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin.

 

It is available in the following dosages:

Synjardy 12.5/1000 mg, 60 tablets

Synjardy 12.5/850 mg, 60 tablets

Synjardy 5/1000 mg, 60 tablets

Synjardy 5/850 mg, 60 tablets